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Abstract: Introduction: In the scenario of chronic non-communicable diseases, obesity stands out as a 
multifactorial disease that can cause several public health problems. Currently, about 30% of the world's 
population is overweight or obese. Estimates suggest that the prevalence of severe obesity in 2030 will be 11%, 
approximately twice the current prevalence. By 2025, Brazil will be in fifth place in the world ranking, with an 
estimated 18.0 million people. The appearance of the new coronavirus (SARS-CoV-2), which causes the disease 
COVID-19, has worsened the comorbidities of obesity. Objective: to explore, through a concise systematic review, 
the main metabolic and immunological relationships in obesity, especially in the presence of COVID-19. Methods: 
The present study followed a concise systematic review model (PRISMA). The search strategy was carried out in 
the databases PubMed, Embase, Ovid and Cochrane Library, Web Of Science, and Scopus. The quality of the 
studies was based on the GRADE instrument and the risk of bias was analyzed according to the Cochrane 
instrument. Results: A total of 76 studies were found that were submitted to the eligibility analysis, and, after 
that, 15 studies of high to medium quality and with risks of bias were selected that do not compromise the 
scientific basis of the studies, we found that obesity is an important predictor of worsening SARS-CoV-2 pathology. 
There are a complex interaction between multiple metabolic, immunological and inflammatory factors that result in 
meta-inflammation. It has been shown that obesity causes dysfunction in the immune system, increasing 
susceptibility to infections and death from sepsis, and increased oxidative stress in the body. SARS-CoV-2 amplifies 
the inflammatory response, enabling greater propensity to alveolar thrombotic microangiopathy and pulmonary 
thromboembolism. Meta-inflammation and insulin resistance with hyperinsulinemia is the main baseline changes in 
obesity. Conclusion: In the COVID-19 scenario, obesity is an important predictor of the worsening of SARS-CoV-2 
pathology, mainly due to the worsening of metainflammation.  
      
Keywords: SARS-CoV-2, COVID-19, Obesity, Meta-inflammation, Metabolism, Immunity. 
 
1. Introduction 
 In the scenario of chronic non-communicable 
diseases, obesity stands out as a multifactorial disease 
that can cause several public health problems [1]. 
Currently, about 30% of the world's population is 
overweight or obese. By 2020, it is estimated that 
more than 60% of the world's population will be 
overweight or obese. Estimates suggest that the 
prevalence of severe obesity in 2030 will be 11%, 
approximately twice the current prevalence [1]. In this 
context, there are 2.0 billion overweight and obese 
people in the world [1]. In the United States, the 
prevalence of obesity is greater than 30.0% for both 
sexes, and obesity is the cause of death for 2.8 million 
people per year, affecting 26% of adults.1 In Europe, 
it is estimated that 10 to 20% of men and 15 to 25% 
of women are obese [1]. 
By 2025, Brazil will find itself in fifth place in 
the world ranking, with an estimated 18.0 million 
people, tending to reach more than 70.0 million [2]. 
Furthermore, in Brazil, this chronic disease has 
increased by 67.8 % in the last thirteen years, rising 
from 11.8% in 2006 to 19.8% in 2018. The highest 
growth rate was among adults aged 25 to 34 years 
(84.2%) and 35 to 44 years (81, 1%). Today, in the 
country, 20.7% of women are obese and 18.7% of 
men [2]. 
Along with the obesity pandemic, the 
appearance of the new coronavirus (SARS-CoV-2), 
which causes COVID-19 disease, has worsened the 
obesity comorbidities [3]. It is necessary to understand 
the mechanisms by which obese patients at greater 
risk of evolving to severe forms of the disease, even 
death. In this sense, immunity plays a decisive role in 
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SARS-CoV-2 infection. The lack of regulation and the 
excessive immune response to the viral stimulus 
exacerbate pro-inflammatory cytokines (cytokine 
storm), reaching the state of hyper inflammation, with 
consequent damage to various tissues of the obese 
[3]. 
Therefore, the occurrence of immune 
dysfunction, greater predisposition to infection, and 
mortality from sepsis is a reality. Obesity was 
correlated with high leukocyte and lymphocyte count 
(except for NK, T suppressor, and cytotoxic T cells), 
with suppression of lymphocyte proliferation of T and 
B lymphocytes and with higher rates of oxidative 
activity and phagocytosis by monocytes and 
granulocytes, demonstrating the consequences of this 
pathology on the immune system.4 In addition to 
these changes, it is known that obesity initially favors 
the development of inflammation in adipose tissue, by 
increasing the production of pro-inflammatory 
adipokines, such as IL-6 and the TNF-α. 
Thus, the proportion between pro-
inflammatory and anti-inflammatory cytokines 
becomes unbalanced [5]. Consequently, damage to 
the vascular system occurs, promoting endothelial 
dysfunction, characterized by a decrease in the 
production of nitric oxide and an increase in the 
synthesis of reactive oxygen species, which establishes 
an inflammatory and oxidative stress state. Regarding 
innate immunity, in obese patients, there is a 
modification of the immune environment in adipose 
tissue [6]. 
In this context, obesity induces a change in 
the profile of macrophages, with an increase in the M1 
phenotype (pro-inflammatory). This effect corresponds 
to an upregulation in inflammatory genes and a 
downregulation in anti-inflammatory genes [7]. 
However, it is not only in adipose tissue that this 
change occurs in cells of the innate immune system. 
Thus, the authors demonstrated that circulating obese 
mononuclear cells are also in a pro-inflammatory state, 
with an increase in the intranuclear factor κB (NF-κB) 
and, consequently, with an increase in the 
transcription of pro- genes. inflammatory drugs 
regulated by it [8]. As a corollary, the innate immune 
response in patients with obesity is altered, resulting in 
an imbalance in the line of defense against infections, 
an increase in the inflammatory response, and 
abnormal activation of T lymphocytes. The primary 
increase in the inflammatory response in obese 
patients works as a predictor for the 
hyperinflammatory state observed in COVID-19. 
Therefore, this primary increase can be amplified by 
the SARS-CoV-2 infection, increasing the production of 
cytokines such as TNF-α, IL-1, and IL-6 [3]. 
Therefore, the present study aimed to explore, 
through a concise systematic review, the main 
metabolic and immunological relationships in obesity, 
especially in the presence of COVID-19. 
 
2. Methods 
2.1. Study Design 
The present study followed a concise 
systematic review model, following the rules of 
systematic review - PRISMA (Transparent reporting of 
systematic reviews and meta-analysis-HTTP: 
//www.prisma-statement.org/). 
 
2.2. Search Strategy and Information 
Sources 
The search strategy was carried out in the 
databases PubMed, Embase, Ovid and Cochrane 
Library, Web Of Science, and Scopus, following the 
following steps: - search for descriptors: SARS-CoV-2. 
COVID-19. Obesity. Meta-inflammation. Metabolism. 
Immunity, and the use of Booleans "and" among 
descriptors and "or" among historical findings. 
 
2.3. Study Quality and Bias Risk 
The quality of the studies was based on the 
GRADE instrument and the risk of bias was analyzed 
according to the Cochrane instrument. 
 
3. Results and Discussion 
A total of 76 studies were found that were 
submitted to the eligibility analysis, and, after that, 15 
studies of high to medium quality and with risks of bias 
were selected that do not compromise the scientific 
basis of the studies (Figure 1). After a complete 
analysis of these selected studies, it was found that 
obesity represents an important predictor of the 
worsening of SARS-CoV-2 pathology. 
There are a complex interaction between 
multiple metabolic, immunological and inflammatory 
factors that result in meta-inflammation. In this sense, 
it was shown that obesity causes dysfunction in the 
immune system, increasing the susceptibility to 
infections and death from sepsis, an increase in 
oxidative stress in the body. Also, SARS-CoV-2 
amplifies the inflammatory response, enabling greater 
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propensity to alveolar thrombotic microangiopathy 
(primary pulmonary thrombosis) and pulmonary 
thromboembolism. Also, meta-inflammation and insulin 
resistance with hyperinsulinemia is the main baseline 
changes in obesity. 
 
Figure 1. Flow Chart of Study Eligibility. 
 
3.1. Major Inflammatory Aspects – Obesity 
The circulating level of cytokines and acute-
phase proteins associated with inflammation is high in 
patients with obesity. Thus, adipocytes secrete various 
cytokines and acute-phase proteins that increase the 
production and circulation of factors related to 
inflammation. The inflammatory process may be due 
to resistance to the action of insulin and other 
disorders associated with obesity, such as 
hyperlipidemia and metabolic syndrome [4]. 
Thus, the association between obesity and 
inflammatory disease is highlighted. There are three 
possibilities, the first of which reflects the production 
and release from organs other than fat, mainly the 
liver (and immune cells). The second explanation is 
that white adipose tissue secretes factors that 
stimulate the production of inflammatory markers by 
the liver and other organs. The third possibility is that 
adipocytes themselves are an immediate source of 
some or several, of these inflammatory markers [4,5]. 
Also, effects such as energy balance sensors 
have been attributed to cytokines. Among all 
adipokines related to inflammatory processes, 
interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), 
leptin and adiponectin stand out [5]. In this context, 
some studies have shown low concentrations of anti-
inflammatory adipokine (adiponectin) associated with 
the occurrence of several types of cancer and high 
concentrations to inhibit the growth of tumors [3-5]. 
Adiponectin and leptin are the most abundant 
adipokines synthesized by adipose tissue, although 
there are others such as TNF-α, IL-6, IL-1, CC-
chemokine ligand 2 (CCL2), a visceral adipose-tissue-
derived serine protease inhibitor (vaspin), and retinol-
binding protein 4 (RBP4) [3]. 
In this sense, the excess of adipose tissue 
increases the production of several adipokines that 
have a great impact on several bodily functions. In this 
case, food intake control and energy balance, immune 
system, insulin sensitivity, angiogenesis, blood 
pressure, lipid metabolism, and body homeostasis 
stand out, situations strongly correlated with 
cardiovascular disease [7]. They stand out as 
adipokines with anti-inflammatory the IL1 receptor 
antagonist (IL-1ra), transforming growth factor-β 
(TGF-β), those produced by Th2 cells (IL-4, IL-5, and 
IL-10) and adiponectin [3]. The imbalance between 
pro and anti-inflammatory cytokines can induce 
inflammatory or hypersensitive responses. Besides, 
high plasma adiponectin concentrations are associated 
with a reduced risk of myocardial infarction in men. 
Adiponectin is inversely proportional to the 
concentration of C-reactive protein (CRP). It can 
downregulate the gene expression of CRP in the 
adipocyte [3]. 
Also, it should be noted that the adipose tissue 
of obese individuals has an upregulation of the 
expression of the angiotensin-converting enzyme 2 
(ECA2), which functions as an input receptor for SARS-
CoV-2 in the cell. Thus, adipose tissue serves as a 
target and a potential viral reservoir. Thus, obesity is a 
pathology that causes damage to the immune system 
and amplifies inflammatory responses and this 
contributes to understanding the interaction between 
COVID-19 and obesity [3]. 
 
3.2. Meta-inflammatory processes of obese 
individuals at COVID-19 
Meta-inflammation describes the junction of 
inflammation with the metabolic changes that occur in 
the body of obese patients [4]. Several toxic mediators 
that contribute to the inflammatory state and tissue 
damage are present in obesity, such as free fatty acids 
(FFA), lipid derivatives toxic substances, such as 
diacylglycerol, toxic nitric oxide metabolites, and 
inflammatory mediators, such as C-reactive protein, 
cytokines, chemokines, macrophages, and TNF-α. The 
imbalance in inflammatory mediators induced by 
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excess nutrients is the basis of meta-inflammation in 
obesity, considered a low-grade chronic inflammatory 
state. Similar to that seen in acute inflammatory 
diseases, obesity can cause multiple organ 
dysfunction. Meta-inflammation leads to myocardial 
dysfunction by direct injury to inflammatory mediators, 
as well as by the dysfunction of other organs [5], 
according to Table 1. 
Table 1. Summary of the main metabolic, 
immunological and inflammatory considerations of the 
relationship between Obesity and COVID-19 [15]. 
 
OBESITY AND COVID-19 
 
 Obesity increases the risk of developing severe 
COVID-19; 
 Obesity increases the risk of young people 
presenting with the severe form of COVID-19; 
 Obesity causes dysfunction in the immune 
system, increasing the susceptibility to 
infections and death from sepsis; 
 Obesity leads to a chronic inflammatory state 
and oxidative stress in the body; 
 SARS-CoV-2 amplifies the inflammatory 
response already originally increased in obese 
people; 
 Adipocytes are potential targets and reservoirs 
for SARS-CoV-2; 
 Obesity-related venous macrocirculatory 
characteristics such as immobilization and 
venous stasis in the lower limbs are related to 
the increased risk of pulmonary embolism. 
Therefore, these conditions typical of obese 
people make them more vulnerable to the 
respiratory manifestations of COVID-19, with a 
greater propensity to alveolar thrombotic 
microangiopathy (primary pulmonary 
thrombosis) and pulmonary thromboembolism; 
 Metainflammation and insulin resistance with 
hyperinsulinemia are the main baseline 
changes in obesity that trigger a series of 
harmful events, resulting in damage to the 
cardiovascular system; 
 Obese patients have comorbidities and a more 
reactive endothelium, which favors the 
evolution to a more severe form of COVID-19; 
 In autopsies performed on patients with 
COVID-19, endothelium, microthrombi, 
neoangiogenesis, and hyaline membrane were 
more evident. 
 The main changes observed in coagulation are 
increased generation of thrombin, D-dimer, 
fibrinogen (initially), prothrombin time, 
reduced fibrinolysis and platelet count;       
 
              Obese patients stand out among the young 
population that evolves to the severe form of COVID-
19. The unfavorable evolution is possible because 
these patients have a more inflamed and hyper-
reactive endothelium, which, under the stimulation of 
SARS-CoV-2, presents an excessive response, 
responsible for the hyper inflammation with cytokine 
storm. As a corollary to the exacerbated inflammatory 
process, the coagulation cascade is unregulated, 
causing hypercoagulability. Therefore, the endothelial 
dysfunction caused by SARS-CoV-2 justifies why 
patients with blood vessel-related comorbidities such 
as cardiovascular disease, hypertension, diabetes, and 
obesity are more likely to develop severe cases of 
COVID-19, even death [3]. 
Post-mortem histological studies revealed a 
picture of lymphocytic endothelium in the lungs, heart, 
kidneys, and liver, as well as cellular necrosis and the 
presence of microthrombi, which, in the lungs, 
worsens respiratory failure. Thus, authors found in 
autopsies evidence of direct viral infection of SARS-
CoV-2 in the endothelial cell and diffuse inflammation. 
The ACE2 receptor is also widely expressed in multi-
organ endothelial cells [8]. 
In this sense, other authors conducted an 
autopsy study that compared the lungs of patients who 
died from COVID-19 versus the lungs of people who 
died from Influenza A (H1N1). The histological pattern 
on the periphery of the lung was a diffuse alveolar 
lesion with perivascular T-cell infiltrate. The lungs of 
patients with COVID-19 also showed distinct vascular 
characteristics, consisting of severe endothelial injury 
associated with the presence of intracellular viruses 
and ruptured cell membranes. Histological analysis of 
pulmonary vessels in patients with COVID-19 showed a 
widespread thrombosis with microangiopathy. Alveolar 
capillary microthrombi were nine times more prevalent 
in patients with COVID-19 than in patients with 
influenza (p<0.001) [9]. 
Also, COVID-19 respiratory failure is related to 
inflammatory changes and coagulation processes in 
the alveolar microcirculation. Thus, alveolar thrombotic 
microangiopathy is a primary thrombosis triggered by 
COVID-19 and differs from pulmonary arterial 
thrombosis, as there is a direct action of the virus on 
the endothelium, which causes diffuse endothelium. 
Thus, it is suggested that the action of SARS-CoV-2 
provides an endothelial stripping due to inflammation, 
leading to significant exposure of tissue factor, 
activating the coagulation cascade and subsequent 
pulmonary thrombotic microangiopathy [10]. 
             In this sense, this process of local activation 
of cytokines can complicate the evolution of 
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pneumonia caused by COVID-19, especially in obese 
patients, since the state of micro thrombosis causes a 
post-thrombotic endothelial dysfunction, activates the 
complement system and the release of cytokines. And, 
when these systems are activated, a continuous state 
of hypercoagulability occurs. As scientific evidence, 
authors have demonstrated the relationship between 
obesity and a higher risk of intubation and mechanical 
ventilation, in addition to higher hospital mortality. In 
this series, 46% of the 1150 patients admitted with 
severe COVID-19 were obese, and invasive mechanical 
ventilation was required in 79% of the 257 patients 
who progressed to a critical form of the disease [11]. 
            This was also reported in a multicenter study 
involving 5,700 hospitalized patients in the 
metropolitan New York area. Obesity has been 
described as the second most frequent comorbidity, 
being present in about 40% of patients with COVID-
19. During the hospitalization of 2634 patients, 14.2% 
were treated in the ICU and 12.2% received invasive 
mechanical ventilation. Mortality for those who 
required mechanical ventilation was 88.1% [12]. 
            Still, other authors observed the relationship 
between obesity and the development of severe 
respiratory manifestations when analyzing 103 
hospitalized patients with COVID-19. They reported 
that 47% of these patients were obese. In this study, 
patients who had a BMI of 30 kg/m2 were among 
those most in need of ICU admission and mechanical 
ventilation [13]. 
           Also, obesity produces hemodynamic changes 
that contribute to the development of structural and 
functional cardiac abnormalities. These changes can 
cause heart failure (HF), even in the absence of other 
comorbidities, such as hypertension and coronary 
artery disease (CAD). Therefore, HF-related to severe 
obesity is called obesity cardiomyopathy. In this 
context, the inflammatory mediators produced by 
adipose tissue are direct mechanisms of cardiac 
dysfunction, and hypertension, diabetes, and CAD are 
indirect mechanisms [14]. 
 
4. Conclusion 
In the COVID-19 scenario, obesity is an 
important predictor of the worsening of SARS-CoV-2 
pathology. There are a complex interaction between 
multiple metabolic, immunological and inflammatory 
factors that result in metainflammation. The global 
population is increasingly overweight, obese, and 
suffering from obesity-related diseases, including many 
metabolic diseases, cardiovascular and systemic 
diseases. In this sense, COVID-19 expressed the 
vulnerability of obesity to viral infection. Global 
awareness is needed to adopt measures to mitigate 
obesity, such as nutritional health, in an attempt to 
reduce the obesity pandemic and, thus, prepare 
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